000069668 001__ 69668
000069668 005__ 20200103141021.0
000069668 0247_ $$2doi$$a10.1016/j.ekir.2017.08.016
000069668 0248_ $$2sideral$$a104658
000069668 037__ $$aART-2018-104658
000069668 041__ $$aeng
000069668 100__ $$aCruzado, J.M.
000069668 245__ $$aParicalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
000069668 260__ $$c2018
000069668 5060_ $$aAccess copy available to the general public$$fUnrestricted
000069668 5203_ $$aIntroduction: Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. Methods: This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium <10 mg/dl were randomized to paricalcitol (PAR) or calcifediol (CAL). The intention-to-treat population (PAR: n = 46; CAL: n = 47) was used for the analysis. The primary endpoint was the percentage of patients with serum iPTH >110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. Results: The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH <70 pg/ml in the PAR group than in the CAL group (63.4% vs. 37.2%; P = 0.03). No differences were observed in bone turnover biomarkers and bone mineral density. The estimated glomerular filtration rate was significantly higher in the CAL group than in the PAR group without differences in albuminuria. In protocol biopsies, interstitial fibrosis and tubular atrophy tended to be higher in the PAR group than in the CAL group (48% vs. 23.8%; P = 0.09). Both medications were well tolerated. Conclusion: Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH <70 pg/ml. These results do not support the use of PAR to treat posttransplantation hyperparathyroidism.
000069668 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/RD16-0009-0003
000069668 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000069668 592__ $$a0.902$$b2018
000069668 593__ $$aNephrology$$c2018$$dQ2
000069668 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000069668 700__ $$aLauzurica, R.
000069668 700__ $$aPascual, J.
000069668 700__ $$aMarcen, R.
000069668 700__ $$aMoreso, F.
000069668 700__ $$0(orcid)0000-0002-2253-7779$$aGutierrez-Dalmau, A.$$uUniversidad de Zaragoza
000069668 700__ $$aAndrés, A.
000069668 700__ $$aHernández, D.
000069668 700__ $$aTorres, A.
000069668 700__ $$aBeneyto, M.I.
000069668 700__ $$aMelilli, E.
000069668 700__ $$aManonelles, A.
000069668 700__ $$aArias, M.
000069668 700__ $$aPraga, M.
000069668 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000069668 773__ $$g3, 1 (2018), 122-132$$pKidney int. rep.$$tKidney International Reports$$x2468-0249
000069668 8564_ $$s375890$$uhttps://zaguan.unizar.es/record/69668/files/texto_completo.pdf$$yVersión publicada
000069668 8564_ $$s123382$$uhttps://zaguan.unizar.es/record/69668/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000069668 909CO $$ooai:zaguan.unizar.es:69668$$particulos$$pdriver
000069668 951__ $$a2020-01-03-14:01:12
000069668 980__ $$aARTICLE